CRISPR-based gene editing therapy approved by the FDA for the first time

In a landmark decision, the FDA greenlit two new drugs for the treatment of sickle cell disease in patients 12 and older, one of which —Vertex’s drug Casgevy — is the first approved use of genome editing technology CRISPR in the US. Bluebird Bio’s Lyfgenia also is a cell-based gene therapy…
Read More

About The Author

Jonathan Jeriah

See author's posts